SNS-032

SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC50s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect[1].

Product Specifications

CAS Number

[345627-80-7]

Product Name Alternative

BMS-387032

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; CDK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SNS-032.html

Purity

99.91

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC(C)(C1=CN=C(CSC2=CN=C(NC(C3CCNCC3)=O)S2)O1)C

Molecular Formula

C17H24N4O2S2

Molecular Weight

380.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Chen R, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113 (19) :4637-45.|[2]Ali MA, et al. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia. 2007 May;9 (5) :370-81.|[3]Conroy A, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 Sep;64 (4) :723-32.|[4]Wu Y, et al. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.Clin Cancer Res. 2012 Apr 1;18 (7) :1966-78. Epub 2012 Mar 23.|[5]Walsby E, et al. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells. Leukemia. 2011 Mar;25 (3) :411-9. Epub 2011 Jan 7.